This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Helicos And MGH Demonstrate Clinical Diagnostic Utility Of Helicos Platform

Helicos BioSciences Corporation (NASDAQ: HLCS) today announced a publication entitled “Amplification-free digital gene expression profiling from minute cell quantities” appearing on line in Nature Methods co-authored by Dr. Daniel A. Haber and colleagues from Massachusetts General Hospital. The paper demonstrates the quantitative capabilities of Helicos’ single-molecule sequencing technology and its potential to reveal important genomic differences when minimal numbers of cells are available for analysis.

“This paper demonstrates significant potential clinical advantages of the single molecule-sequencing platform. The method can effectively utilize a very small number of cells for accurate molecular characterization, while being less prone to errors and representational biases seen with other sequencing techniques,” said Daniel A. Haber, M.D., Ph.D., Director of the Massachusetts General Hospital Cancer Center.

“Our research with Dr. Haber and his team supports our collective interest in utilizing our single-molecule sequencing technology to improve clinical care for patients,” commented Dr. Patrice Milos, Chief Scientific Officer at Helicos. “Helicos is assessing techniques described in this publication for their potential to advance molecular diagnostic assays for patients suffering from breast and ovarian cancer.”

In this study, single RNA molecules extracted from cell lysates of malignant and nonmalignant mouse and human cells were quantitated following direct capture, first strand cDNA synthesis and sequencing directly on the HeliScope Flow Cell surface. The experimental model systems demonstrate the ability to work with small cell numbers to accurately and reproducibly identify differentially expressed genes in closely related cell types.

The joint research also demonstrated the ability to apply the same methodology to RNA isolated from formal-fixed paraffin embedded (FFPE) tissues providing a potential new method for studying stored clinical specimens.

Additional information can be found in Helicos' Annual Report on Form 10-K for the fiscal year ended December 31, 2009, as filed with the SEC on April 15, 2010, together with its Quarterly Report on Form 10-Q for the first fiscal quarter 2010, as filed with the SEC on May 17, 2010. These reports include a discussion regarding the company's need to raise capital to pursue its new business of developing molecular diagnostic tests, disclosures regarding the company's operational results and liquidity position, and additional disclosures regarding other risks and uncertainties faced by Helicos.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.04 -0.21%
FB $117.40 -0.35%
GOOG $703.32 0.27%
TSLA $210.43 -0.52%
YHOO $36.88 -0.16%


Chart of I:DJI
DOW 17,648.59 -12.12 -0.07%
S&P 500 2,048.45 -2.18 -0.11%
NASDAQ 4,714.6390 -2.4550 -0.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs